We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Powerful Innovations in Diagnostics Unveiled at EuroMedLab 2015

By LabMedica International staff writers
Posted on 30 Jun 2015
Print article
New systems presented by Roche include a new standard for immunology testing, an integrated platform for hematology diagnostics, and a high-throughput analyzer to perform HbA1c tests for blood glucose management. Also, evidence was presented for a high-sensitivity cardiac troponin test to provide earlier and more accurate diagnosis of heart attacks.

Diagnostics account for a small fraction of worldwide healthcare spending but contribute much to informed medical decision-making. Innovations in diagnostics can, therefore, make a major impact. At the 21st annual IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicines (EuroMedLab 2015; Paris, France), Roche (Basel, Switzerland) unveiled a series of new diagnostic technologies.

“Diagnostics have proven to be one of the most influential elements in the healthcare value cycle,” says Jean-Claude Gottraux, head of Roche Professional Diagnostics. New members of the cobas family were introduced: cobas e 801 module, cobas m 511 analyzer, and cobas c 513 analyzer. The cobas e 801 module for immunology testing is a platform capable of carrying out double the number of tests compared to the previous version (cobas e 602). The system requires smaller blood samples, making it particularly suitable for diagnosis of vulnerable groups such as neonates, cancer and ICU patients, and elderly people. The reduced sample volume also leads to less liquid waste, thereby decreasing environmental impact. Commercial availability is planned for 2016.

The cobas m 511 integrated hematology analyzer has the potential to transform hematology testing practices. It integrates 3 instruments into one efficient system, enabling labs to save space, time, and money. With a low required blood volume of 30 microliters for a complete hematology result including morphology assessment, cobas m 511 is also suitable for patients where blood volumes are particularly precious. The system is scheduled for launch in 2016.

The cobas c 513 blood glucose analyzer is a dedicated, high-throughput HbA1c analyzer uniquely suitable for diagnosis, monitoring, and risk identification of diabetes patients. It sets new standards of lab efficiency as well as safety for lab personnel. The analyzer is scheduled for commercial availability in Q4-2015.

In cardiovascular testing, Roche has demonstrated the impact of improved troponin testing to detect more heart attacks (acute myocardial infarctions (AMIs)). Roche’s Elecsys cardiac Troponin T – high-sensitive (cTnT-hs) test detects cardiac troponin. In combination with electrocardiogram (ECG), troponin tests have become the gold standard for AMI diagnosis. “With previous generations of troponin tests, the time to diagnose AMI was 6 hours, which has been brought down to 3 hours,” said Christian Mueller, professor of cardiology at the University of Basel, Switzerland, “Increasing evidence shows that the time needed to make decisions in cases of suspected AMI can be further brought down to just 1 hour.” Used in conjunction with a novel approach for result interpretation, the high sensitivity of Roche’s cTnT-hs assay helps reduce time-to-diagnosis to 1 hour. Every hour saved is of critical importance for patients, and faster, more accurate diagnosis is beneficial to the healthcare system overall as patients with symptoms suggestive of AMI account for approximately 10%–20% of all emergency room consultations.

Related Links:

Roche 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Cancer Mutation Profiling Liquid Kit
OncoScreen Plus

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.